ONCAlert | Upfront Therapy for mRCC
Videos  >  

Dr. Sylvia Adams on Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer

Sylvia Adams, MD
Published Online:10:18 PM, Wed November 11, 2015

 

Sylvia Adams, MD, medical oncologist, NYU Langone Medical Center, talks about the the importance of tumor-infiltrating lymphocytes (TILS) and how they can mark which patients will respond to immunotherapy use in triple negative breast cancer (TNBC). She discussed this topic at the recent Chemotherapy Foundation Symposium. 

 

She says that according to a study on 500 patients, these lymphocytes predict response to treatment in TNBC patients. She adds that the same results were seen in other investigators around the globe. This information is important to medical oncologists because it shows what types of breast cancers will potentially respond to immunotherapies.

Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.